Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 25/100

ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been initiated against ADMA Biologics, Inc. by Bragar Eagel & Squire in New Jersey, representing individuals who acquired ADMA securities between August 9, 2024, and March 25, 2026. The lawsuit claims that the company made misleading statements and failed to disclose significant risks regarding its operations, including allegations of using channel stuffing to inflate revenues. Following a critical report by Culper Research, ADMA's stock experienced a significant decline. Investors interested in joining the lawsuit have until August 10, 2026, to apply as lead plaintiff.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against ADMA Biologics for allegedly making false and misleading statements.
  • The lawsuit claims that ADMA engaged in an undisclosed related party transaction.
  • ADMA's stock price fell 16.63% following the publication of a report alleging that the reported growth was artificial.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ADMA To Contact Him Directly To Discuss Their Options
If you purchased or acquired ADMA Biologics securities between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired ADMA Biologics securities between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”). Investors have until August 10, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding ADMA’s business, operations, and prospects, including allegations that: (1) ADMA engaged in an undisclosed related party transaction; (2) ADMA used channel stuffing to create an appearance of revenue; and (3) ADMA lacked adequate internal controls.
On March 24, 2026, Culper Research published a short report on ADMA, alleging that "ADMA's reported growth is a fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor" and "estimat[ing] that, absent channel stuffing, ADMA revenues declined 3% in 2025 vs. +20% reported."
Following publication of the Culper report, ADMA's stock price fell $2.26 per share, or 16.63%, to close at $11.33 per share on March 24, 2026.
If you purchased or otherwise acquired ADMA shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who should contact Brandon Walker regarding ADMA losses?

Investors who acquired ADMA Biologics securities between August 9, 2024, and March 25, 2026, should reach out.

What is the deadline for lead plaintiff application in the ADMA lawsuit?

Investors have until August 10, 2026, to apply to be the lead plaintiff.

What allegations are made against ADMA in the lawsuit?

The lawsuit claims ADMA made false statements, engaged in undisclosed transactions, and lacked controls.

What caused the drop in ADMA's stock price on March 24, 2026?

ADMA's stock fell after a report alleged revenue manipulation and undisclosed dealings.

How can I inquire further about my rights as an investor?

Contact Brandon Walker or Melissa Fortunato via email or phone for more information.

Last updated: Jun 17, 2026